# US 2024/0043503 A1 · Compositions and methods for the treatment of immunodeficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0043503 A1
- Document ID: US20240043503A1
- Status: Published application
- Kind: A1
- Application number: 18/378,021
- Filed: 2023-10-09
- Published: 2024-02-08
- Earliest claimed: 2014-10-28
- Assignees: Adma Biomanufacturing, LLC
- Applicants: Adma Biomanufacturing, LLC
- Inventors: Adam S. Grossman; James Mond; Jerrold B. Grossman; Dov A. Goldstein
- Web page: https://patentgrep.com/patent/US20240043503A1

## CPC

- C07K 16/06: from serum
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61K 39/39516: {from serum, plasma}
- A61K 39/42: viral
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- C07K 16/08: against material from viruses
- C07K 16/102: Coronaviridae (F)
- C07K 16/106: Picornaviridae (F), e.g. hepatitis A virus
- C07K 16/11: Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
- C07K 16/1203: Gram-negative bacteria
- C07K 16/1232: Escherichia (G)
- C07K 16/1242: {from Pasteurellaceae (F), e.g. Haemophilus influenza}
- C07K 16/1271: Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
- C07K 16/1275: Streptococcus (G)
- C07K 16/1282: Clostridium (G)
- C07K 16/1285: {from Corynebacterium (G)}
- C07K 16/1289: Mycobacteriaceae (F)
- G01N 33/6854: {Immunoglobulins}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/10: characterized by their source of isolation or production
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).

## Claims

### Claim 1

An immunotherapeutic composition comprising:
A) immune globulin prepared from a pooled plasma composition comprising plasma samples from 500 or more human plasma donors, wherein the pooled plasma composition has a final RSV neutralization titer of at least 1800, and an antibody titer for coronavirus that is at least 1.3 times greater than the antibody titer in a control sample, wherein the control sample is a mixture of plasma samples obtained from 500 or more random human plasma donors, wherein less than 50% of the donor plasma samples used for pooling are from donors with a final RSV neutralization titer of at least 1800; and
B) a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The immunotherapeutic composition of claim 1, further comprising: C) an anti-toxin agent.

### Claim 3 (depends on 2)

The immunotherapeutic composition of claim 2, wherein the anti-toxin agent is a mono-specific, bi-specific or multi-specific antibody with specificity toward a bacterial or fungal toxin.

### Claim 4 (depends on 3)

The immunotherapeutic composition of claim 3, wherein the bacterial or fungal toxin is selected from the group consisting of Botulinum neurotoxin, Tetanus toxin, E. coli toxin, Clostridium difficile toxin, Vibrio RTX toxin, Staphylococcal toxins, Cyanobacteria toxin, and mycotoxins.

### Claim 5 (depends on 1)

The immunotherapeutic composition of claim 1, wherein the pooled plasma composition comprises neutralizing antibodies specific for one or more of Corynebacterium diphtheria, measles virus, and polio virus.

### Claim 6 (depends on 1)

The immunotherapeutic composition of claim 1, further comprising a biologically active agent selected from the group consisting of an anti-inflammatory agent, an anti-microbial agent, an antihistamine, a cytokine, and a chemokine.

### Claim 7 (depends on 1)

The immunotherapeutic composition of claim 1, further comprising an immunotherapeutic agent selected from the group consisting of a recombinant antibody, an antibody fragment, an antibody-like molecule, a monoclonal antibody, an antiviral, an immunotherapeutic protein and an immunotherapeutic small molecule.

### Claim 8 (depends on 1)

The immunotherapeutic composition of claim 1, further comprising an anti-inflammatory agent selected from the group consisting of a recombinant antibody, an antibody fragment, a monoclonal antibody, an anti-inflammatory protein and an anti-inflammatory small molecule.

### Claim 9 (depends on 1)

The immunotherapeutic composition of claim 1, wherein the coronavirus is coronavirus OC43 and/or coronavirus 229E.

### Claim 10 (depends on 1)

The immunotherapeutic composition of claim 1, further comprising an antibody titer for parainfluenza virus 1, parainfluenza virus 2, influenza A virus, influenza B virus, and/or metapneumovirus that is at least 1.3 times greater than the antibody titer in the control sample.

### Claim 11 (depends on 1)

The immunotherapeutic composition of claim 1, wherein 30-45% of the donor plasma samples used for pooling are from donors with a final RSV neutralization titer of at least 1800.

### Claim 12

A method of providing immunotherapy to a subject comprising administering to the subject a therapeutically effective amount of an immunotherapeutic composition comprising:
A) immune globulin prepared from a pooled plasma composition comprising plasma samples from 500 or more human plasma donors, wherein the pooled plasma composition has a final RSV neutralization titer of at least 1800, and an antibody titer for coronavirus that is at least 1.3 times greater than the antibody titer in a control sample, wherein the control sample is a mixture of plasma samples obtained from 500 or more random human plasma donors, wherein less than 50% of the donor plasma samples used for pooling are from donors with a final RSV neutralization titer of at least 1800; and
B) a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject has an immunodeficiency.

### Claim 14 (depends on 12)

The method of claim 12, wherein the subject has a primary immunodeficiency disease (PIDD).

### Claim 15 (depends on 12)

The method of claim 12, wherein the subject is selected from the group consisting of an end stage renal disease (ESRD) patient, a patient on immunosuppressive therapy, an AIDS patient, a diabetic patient, a neonate, a transplant patient, a patient with malfunctioning immune system, an elderly person, a patient with autoimmune disease, a burn patient, a cancer patient, and a patient in an acute care setting.

### Claim 16 (depends on 12)

The method of claim 12, wherein the immunotherapy is used to treat and/or prevent infection in the subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the infection is caused by a pathogen selected from the group consisting of respiratory syncytial virus (RSV), parainfluenza virus, coronavirus, influenza virus, and metapneumovirus.

### Claim 18 (depends on 12)

The method of claim 12, wherein the immunotherapy is used to treat a respiratory infection in the subject.

### Claim 19 (depends on 12)

The method of claim 12, wherein the immunotherapeutic composition is intravenously administered in a single dose to provide between 250-2500 milligram (mg) immune globulin per kilogram (kg) to the subject.

### Claim 20 (depends on 12)

The method of claim 12, wherein the immunotherapeutic composition is administered to the subject every four weeks.
